NUVB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	990 255
Average Volume	1.33M
Market Cap	580.00M
EPS	$0 ( 2024-03-20 )
Next earnings date	( $-0.0800 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.60
ATR14	$0.00400 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Cui Xiangmin	Buy	4 183 002	Class A Common Stock
2024-04-09	Cui Xiangmin	Buy	1 675 236	Class A Common Stock
2024-04-09	Cui Xiangmin	Buy	314 106	Class A Common Stock
2024-04-09	Cui Xiangmin	Buy	0
2024-04-09	Sjogren Colleen	Buy	500 000	Stock Option (Right to Buy)

INSIDER POWER
94.10
Last 97 transactions
Buy: 43 735 081 \| Sell: 11 578 450

Volume Correlation

Long: -0.01 (neutral)

Short: 0.58 (weak)

Signal:(49.178) Neutral

Panacea Acquisition Corp. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Panacea Acquisition Corp. Correlation - Currency/Commodity

0.79
( moderate )

0.60
( weak )

0.00
( neutral )

0.65
( weak )

-0.54
( weak negative )

Panacea Acquisition Corp. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-222 000 (0.00 %)
EPS:	$-0.350

Q4	2023
Revenue:	$0
Gross Profit:	$-55 000.00 (0.00 %)
EPS:	$-0.0630

Q3	2023
Revenue:	$0
Gross Profit:	$-55 000.00 (0.00 %)
EPS:	$-0.0897

Q2	2023
Revenue:	$0
Gross Profit:	$-38 000.00 (0.00 %)
EPS:	$-0.0943

Financial Reports:

No articles found.

Panacea Acquisition Corp.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.